Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

When Opportunity Knocks: Eisai Turns To Business Development

Apr 15 2013

Related Content

AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013

Mar 25 2013

Arena Finds Antidote For <em>Belviq</em>’s Theoretical Risk Of Valvulopathy In Mechanistic Studies

Oct 01 2012

<em>Dacogen</em> Leukemia Indication Would Require New Clinical Trial, FDA Tells Eisai

Mar 07 2012

Eisai Will Try For <em>Halaven</em> Label Expansion, Despite Phase III Failure

Jul 10 2012

Takeda’s Strategic Run Up To Nycomed

Jul 30 2012

Epizyme Builds A Cancer Company At Mach Speed

May 23 2012

Affymax Considers Bankruptcy As Omontys Investigation Continues

Mar 19 2013

Related Companies

Eisai Co., Ltd.

Ligand Pharmaceuticals, Inc.

Morphotek

Eisai Co., Ltd.

Pfizer Inc.

Johnson & Johnson

Abbott

Arena Pharmaceuticals, Inc.

Orion

Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

Affymax, Inc.

AMAG Pharmaceuticals Inc.

Epizyme, Inc.

Orexigen Therapeutics, Inc.

Vivus, Inc.

Novartis AG

Bausch Health Companies Inc.

Arbor Pharmaceuticals, LLC

IQVIA Holdings Inc.

SFJ Pharmaceuticals, Inc

GSK plc

BioArctic AB

Novartis AG

Epizyme, Inc.

Additional Topics

Deals BioPharmaceutical

More from Deal-Making

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window